Catalyst Event
Viatris Inc (VTRS) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/23/2026, 12:00:00 AM
Japan's Ministry of Health, Labour and Welfare (MHLW) approved Effexor® SR capsules for the treatment of adults with generalized anxiety disorder (GAD), making it the first and only approved treatment for this condition in Japan.
Korean Translation
일본 후생노동성(MHLW)이 성인 범불안장애(GAD) 치료제로 에페서® SR 캡슐을 승인함. 이는 일본에서 해당 질환에 대해 최초이자 유일하게 승인된 치료제임.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM